ISA Pharmaceuticals long term study confirms efficacy of our T-cell activating immunotherapy in combination with checkpoint inhibitor

  • Data published in the Journal of ImmunoTherapy of Cancer confirms efficacy of combination treatment (ISA101b + anti-PD1)
  • Deep and durable responses have a profound positive effect on patient prognosis with patients disease-free for more than 44 months
  • Improved tumour infiltration by immune cells predicted response to therapy

Oegstgeest, March 1, 2022 – ISA today announces the publication of extension data from a key study using lead product ISA101b in the Journal of ImmunoTherapy of Cancer. The study, ISA101 and nivolumab for HPV-16+ cancer: updated clinical efficacy and immune correlates of response, is performed by Guimaraes Sousa, Michael Curran, Bonnie Glisson et al. in collaboration with the MD Anderson Cancer Center in Houston, Texas.

Read more…